CTRI/2023/09/057217尚未招募Unknown
Clinical Profile, Visual Outcome and quality of Life in patients undergoing Pan retinal photocoagulation for Proliferative diabetic Retinopathy - NI
Jawaharlal Nehru Medical College SAWANGI0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients with diabetes type 1 or diabetes type 2 having Proliferative diabetic retinopathy.
- •Patients of age 40 years or above
- •Patients willing to undergo and fit for pan retinal Photocoagulation Procedure.
- •Patients consenting for follow up visits at 1 month, 6 month and 1 year.
排除标准
- •Patients with non-proliferative diabetic retinopathy (NPDR)/ severe NPDR.
- •Patients receiving additional ocular intervention such as intravitreal injection or cataract surgery.
- •Patients with gestational diabetes.
- •Patients with corneal opacities deleteriously affecting their visual acuity.
- •Patient below age of 40 years.
研究者
相似试验
招募中
不适用
The quantification of vision-related quality of life (QOL) using VFQ-25 questionnaireJPRN-UMIN000025424Department of Ophthalmology, Faculty of Medicine, University of Tsukuba50
进行中（未招募）
不适用
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2006-001449-33-SESchering Plough Institute, A Division of Schering Corporation600
进行中（未招募）
不适用
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCEEUCTR2006-001449-33-CZSchering-Plough Research Institute, A Division of Schering Corporation600
进行中（未招募）
1 期
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). Estudio de la eficacia, seguridad y calidad de vida (cdv) en pacientes con urticaria crónica idiopática tratados con aerius comprimidos (5, 10 ó 20 mg) una vez al día - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1 Level: LLT Classification code 10021247 Term: Idiopathic urticariaEUCTR2006-001449-33-ESIntegrated Therapeutics Group Incorporated (ITGI)600
进行中（未招募）
不适用
A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). - ACCESubjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be between 10-30, inclusive, at the end of the baseline week (entry period).MedDRA version: 8.1Level: LLTClassification code 10021247Term: Idiopathic urticariaEUCTR2006-001449-33-GRSchering Plough Research Institute, A Division of Schering Corporation600